Genetic Tech. (GENE), Complete Genomics (GNOM) See Profit-Taking Following Positive Cancer Report
Tweet
Share
E-mailGet Alerts ROSG Hot Sheet
Join SI Premium – FREE
Following a nice surge in share price Thursday on news that a recent study suggests genome screens on healthy people may offer key hints about their risks of cancer, Rosetta Genomics (Nasdaq: ROSG), Genetic Technologies Ltd. (Nasdaq: GENE), and Complete Genomics (Nasdaq: GNOM) are seeing investors take profits Friday.
Rosetta moved 3.3 percent while Complete saw a better jump at 12.9 percent and Genetic Tech rose 13 percent. Today, Rosetta is down 4 percent, Complete is off about 6 percent, and Genetic Tech is 7.3 percent lower.
For more on the report, click here.
Rosetta moved 3.3 percent while Complete saw a better jump at 12.9 percent and Genetic Tech rose 13 percent. Today, Rosetta is down 4 percent, Complete is off about 6 percent, and Genetic Tech is 7.3 percent lower.
For more on the report, click here.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
